Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

被引：0

作者：

Laurie E. McLouth

Yue Zheng

Stephanie Smith

F. Stephen Hodi

Uma N. Rao

Gary I. Cohen

Thomas T. Amatruda

Shaker R. Dakhil

Brendan D. Curti

Ibrahim Nakhoul

Sreenivasa R. Chandana

Charles L. Bane

David E. Marinier

Sandra J. Lee

Vernon K. Sondak

John M. Kirkwood

Ahmad A. Tarhini

Lynne I. Wagner

机构：

[1] University of Kentucky,Department of Behavioral Science, College of Medicine, Markey Cancer Center

[2] Dana-Farber Cancer Institute—ECOG-ACRIN Biostatistics Center,Nancy N. and J.C. Lewis Cancer and Research Pavilion

[3] St. Joseph’s/Candler,undefined

[4] Dana-Farber Cancer Institute/Harvard Cancer Center,undefined

[5] University of Pittsburgh Cancer Institute,undefined

[6] Greater Baltimore Medical Center,undefined

[7] Minnesota Oncology,undefined

[8] Ascension Via Christi Hospitals,undefined

[9] Earle A. Chiles Research Institute,undefined

[10] Providence Cancer Institute,undefined

[11] Regional Cancer Center at Indian Path Community Hospital,undefined

[12] Cancer and Hematology Centers of Western Michigan/Cancer Research Consortium of West Michigan NCORP,undefined

[13] Good Samaritan Hospital-Dayton,undefined

[14] Gundersen Health System,undefined

[15] Moffitt Cancer Center,undefined

[16] Atrium Health Wake Forest Baptist Comprehensive Cancer Center,undefined

来源：

Quality of Life Research | 2023年 / 32卷

关键词：

Ipilimumab; Melanoma; Adjuvant therapy; Interferon; Patient-reported outcomes; Quality of life;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：183 / 196

页数：13

共 50 条

[1] Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609
McLouth, Laurie E.
Zheng, Yue
Smith, Stephanie
Hodi, F. Stephen
Rao, Uma N.
Cohen, Gary, I
Amatruda, Thomas T.
Dakhil, Shaker R.
Curti, Brendan D.
Nakhoul, Ibrahim
Chandana, Sreenivasa R.
Bane, Charles L.
Marinier, David E.
Lee, Sandra J.
Sondak, Vernon K.
Kirkwood, John M.
Tarhini, Ahmad A.
Wagner, Lynne, I
QUALITY OF LIFE RESEARCH, 2023, 32 (01) : 183 - 196
[2] Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Tarhini, Ahmad A.
Lee, Sandra J.
Hodi, F. Stephen
Rao, Uma N. M.
Cohen, Gary I.
Hamid, Omid
Hutchins, Laura F.
Sosman, Jeffrey A.
Kluger, Harriett M.
Eroglu, Zeynep
Koon, Henry B.
Lawrence, Donald P.
Kendra, Kari L.
Minor, David R.
Lee, Carrie B.
Albertini, Mark R.
Flaherty, Lawrence E.
Petrella, Teresa M.
Streicher, Howard
Sondak, Vernon K.
Kirkwood, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 567 - +
[3] A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (US Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
Tarhini, Ahmad A.
Lee, Sandra J.
Hodi, F. Stephen
Rao, Uma N. M.
Cohen, Gary I.
Hamid, Omid
Hutchins, Laura Fulper
Sosman, Jeffrey Alan
Kluger, Harriet M.
Sondak, Vernon K.
Koon, Henry B.
Lawrence, Donald P.
Kendra, Kari Lynn
Minor, David R.
Lee, Carrie B.
Albertini, Mark R.
Flaherty, Lawrence E.
Petrella, Teresa M.
Kirkwood, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
Tarhini, Ahmad A.
Lee, Sandra J.
Hodi, F. Stephen
Rao, Uma N. M.
Cohen, Gary Irvin
Hamid, Omid
Hutchins, Laura Fulper
Sosman, Jeffrey Alan
Kluger, Harriet M.
Sondak, Vernon K.
Koon, Henry B.
Lawrence, Donald P.
Kendra, Kari Lynn
Minor, David R.
Lee, Carrie B.
Albertini, Mark R.
Flaherty, Lawrence E.
Petrella, Teresa M.
Kirkwood, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma
Gogas, H.
Dafni, U.
Bafaloukos, D.
Polyzos, A.
Kokkalis, G.
Kalofonos, H. P.
Fountzilas, G.
Skarlos, D.
Tsoutsos, D.
Pectasides, D.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[6] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
Pectasides, Dimitrios
Dafni, Urania
Bafaloukos, Dimitrios
Skarlos, Dimosthenis
Polyzos, Aristidis
Tsoutsos, Dimosthenis
Kalofonos, Haralambos
Fountzilas, George
Panagiotou, Petros
Kokkalis, George
Papadopoulos, Othon
Castana, Ourania
Papadopoulos, Stefanos
Stavrinidis, Elias
Vourli, Georgia
Ioannovich, John
Gogas, Helen
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
[7] Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
Jonasch, E
Kumar, UN
Linette, GP
Hodi, FS
Soiffer, RJ
Ryan, BF
Sober, AJ
Mihm, MC
Tsao, H
Langley, RG
Cosimi, BA
Gadd, MA
Tanabe, KK
Souba, W
Haynes, HA
Barnhill, R
Osteen, R
Haluska, FG
CANCER JOURNAL, 2000, 6 (03): : 139 - 145
[8] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma
Agarwala, Sanjiv S.
Gray, Robert J.
Wong, Michael K. K.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E82 - E83
[9] Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma
Mitchell, Malcolm S.
Abrams, Judith
Thompson, John A.
Kashani-Sabet, Mohammed
DeConti, Ronald C.
Hwu, Wen-Jen
Atkins, Michael B.
Whitman, Eric
Ernstoff, Marc S.
Haluska, Frank G.
Jakowatz, James G.
Das Gupta, Tapas K.
Richards, Jon M.
Samlowski, Wolfram E.
Costanzi, John J.
Aronson, Frederick R.
Deisseroth, Albert B.
Dudek, Arkadiusz Z.
Jones, Vicky E.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 2078 - 2085
[10] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma Reply
Pectasides, Dimitrios
Dafni, Urania
Gogas, Helen
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E84 - E84

← 1 2 3 4 5 →